<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu YL</submitter><funding>Kartigen Biomedical Inc.</funding><pagination>3029</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8466236</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(18)</volume><pubmed_abstract>Here, we aimed to investigate the safety and preliminary efficacy of Kartigen®, a matrix with autologous bone marrow mesenchymal stem cell-derived chondrocyte precursors embedded in atelocollagen. As a surgical graft, Kartigen® was implanted onto the cartilage defects at the weight-bearing site of the medial femoral condyle of the knee. Fifteen patients were enrolled and stratified into two groups, undergoing either Kartigen® implantation (n = 10) or microfracture (control group, n = 5). The primary endpoint was to evaluate the safety of Kartigen® by monitoring the occurrence of adverse events through physician queries, physical examinations, laboratory tests, and radiological analyses for 2 years. There were no infections, inflammations, adhesions, loose body, or tumor formations in the K</pubmed_abstract><journal>Polymers</journal><pubmed_title>Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial.</pubmed_title><pmcid>PMC8466236</pmcid><funding_grant_id>NA</funding_grant_id><pubmed_authors>Liu TT</pubmed_authors><pubmed_authors>Liu YL</pubmed_authors><pubmed_authors>Shih TT</pubmed_authors><pubmed_authors>Chang CH</pubmed_authors><pubmed_authors>Wang JH</pubmed_authors><pubmed_authors>Yang MC</pubmed_authors><pubmed_authors>Lin FH</pubmed_authors><pubmed_authors>Liu HC</pubmed_authors><pubmed_authors>Yen CC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial.</name><description>Here, we aimed to investigate the safety and preliminary efficacy of Kartigen®, a matrix with autologous bone marrow mesenchymal stem cell-derived chondrocyte precursors embedded in atelocollagen. As a surgical graft, Kartigen® was implanted onto the cartilage defects at the weight-bearing site of the medial femoral condyle of the knee. Fifteen patients were enrolled and stratified into two groups, undergoing either Kartigen® implantation (n = 10) or microfracture (control group, n = 5). The primary endpoint was to evaluate the safety of Kartigen® by monitoring the occurrence of adverse events through physician queries, physical examinations, laboratory tests, and radiological analyses for 2 years. There were no infections, inflammations, adhesions, loose body, or tumor formations in the K</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2025-04-22T07:56:44.562Z</modification><creation>2022-02-11T11:27:58.834Z</creation></dates><accession>S-EPMC8466236</accession><cross_references><pubmed>34577930</pubmed><doi>10.3390/polym13183029</doi></cross_references></HashMap>